Content Type: Article

  • Wages for default of acceptance and crediting of other income – practical tips

    Wages for default of acceptance and crediting of other income – practical tips

    ARTICLE

    Wages for default of acceptance and crediting of other income – practical tips

    March 1, 2024

    Read time: 2 min

    Key takeaways
    Overview

    The HR News blog provides regular updates on recent developments in German employment law (in German). The latest blog post provides insights on “Wages for default of acceptance and crediting of other income – practical tips”.

    Visit the blog and/or register now for regular HR NEWS updates (in German).

    In depth
    Authors
    More insights

  • Status determination and legal tech compliance check

    Status determination and legal tech compliance check

    ARTICLE

    Status determination and legal tech compliance check

    February 8, 2024

    Read time: 2 min

    Key takeaways
    Overview

    The HR News blog provides regular updates on recent developments in German employment law (in German). The latest blog post provides insights on “Status determination and legal tech compliance check”.

    Visit the blog and/or register now for regular HR NEWS updates (in German).

    In depth
    Authors
    More insights

  • Discrimination in the application process? What you as an employer should know now

    Discrimination in the application process? What you as an employer should know now

    ARTICLE

    Discrimination in the application process? What you as an employer should know now

    February 16, 2024

    Read time: 2 min

    Key takeaways
    Overview

    The HR News blog provides regular updates on recent developments in German employment law (in German). The latest blog post provides insights on “Discrimination in the application process? What you as an employer should know now”.

    Visit the blog and/or register now for regular HR NEWS updates (in German).

    In depth
    Authors
    More insights

  • Unfounded anonymous criticism of the boss – review platform must name or delete names

    Unfounded anonymous criticism of the boss – review platform must name or delete names

    ARTICLE

    Unfounded anonymous criticism of the boss – review platform must name or delete names

    February 22, 2024

    Read time: 2 min

    Key takeaways
    Overview

    The HR News blog provides regular updates on recent developments in German employment law (in German). The latest blog post provides insights on “Unfounded anonymous criticism of the boss – review platform must name or delete names”.

    Visit the blog and/or register now for regular HR NEWS updates (in German).

    In depth
    Authors

    Dr. Thomas Gennert

    Partner

    Düsseldorf

    More insights

  • (External) managing director – employer representative or “just” employee?

    (External) managing director – employer representative or “just” employee?

    ARTICLE

    (External) managing director – employer representative or “just” employee?

    February 23, 2024

    Read time: 2 min

    Key takeaways
    Overview

    The HR News blog provides regular updates on recent developments in German employment law (in German). The latest blog post provides insights on “(External) managing director – employer representative or “just” employee?”.

    Visit the blog and/or register now for regular HR NEWS updates (in German).

    In depth
    Authors
    More insights

  • Comprehensive corporate responsibility: New case law facilitates GDPR fines

    Comprehensive corporate responsibility: New case law facilitates GDPR fines

    ARTICLE

    Comprehensive corporate responsibility: New case law facilitates GDPR fines

    February 26, 2024

    Read time: 2 min

    Key takeaways
    Overview

    The HR News blog provides regular updates on recent developments in German employment law (in German). The latest blog post provides insights on “Comprehensive corporate responsibility: New case law facilitates GDPR fines”.

    Visit the blog and/or register now for regular HR NEWS updates (in German).

    In depth
    Authors

    Dr. Philip Uecker

    Associate

    Düsseldorf

    More insights

  • Eid and bridging days: what if everyone wants a vacation?

    Eid and bridging days: what if everyone wants a vacation?

    ARTICLE

    Eid and bridging days: what if everyone wants a vacation?

    April 11, 2024

    Read time: 2 min

    Key takeaways
    Overview

    The HR News blog provides regular updates on recent developments in German employment law (in German). The latest blog post provides insights on “Eid and bridging days: what if everyone wants a vacation?”.

    Visit the blog and/or register now for regular HR NEWS updates (in German).

     

    In depth
    Authors
    More insights

  • Maryland Joins Growing Ranks and Passes Its Own Consumer Data Privacy Law

    Maryland Joins Growing Ranks and Passes Its Own Consumer Data Privacy Law

    ARTICLE / CLIENT ALERT

    Maryland Joins Growing Ranks and Passes Its Own Consumer Data Privacy Law

    April 10, 2024

    Read time: 8 min

    Key takeaways
    Overview

    Consult our interactive state privacy law map to learn more about all of the enacted state consumer privacy laws.

    On April 6, 2024, the Maryland Legislature passed a comprehensive privacy bill, sending the Maryland Online Data Privacy Act of 2024 (MODPA) to Governor Wes Moore’s desk for signature into law. The law, which would take effect October 1, 2025, is similar to prior state consumer privacy laws but has several unique provisions, which likely will require companies subject to MODPA to adjust their state law compliance programs. The good news, however, is that while the law would take effect October 1, 2025, it will not “have any effect on or application to any personal data processing activities before April 1, 2026.”

    In depth

    Who Does MODPA Apply To?

    MODPA applies to any person who conducts business in Maryland or provides products or services that are targeted to Maryland residents and, during the immediately preceding calendar year, either:

    • Controlled or processed the personal data of at least 35,000 Maryland consumers (excluding personal data controlled or processed solely for the purpose of completing a payment transaction)
    • Controlled or processed the personal data of at least 10,000 Maryland consumers and derives more than 20% of their gross revenue from the sale of personal data.

    Both triggering scenarios are materially lower than a majority of other similar state consumer privacy laws, except for the recently passed New Hampshire Privacy Act.

    Who Is a “Consumer”?

    MODPA follows the majority of the other states with consumer privacy laws and defines a consumer as an individual who is a resident of Maryland and acting only in the individual context (i.e., excluding employment or commercial actors).

    What Is “Personal Data”?

    Another familiar definition is that of “personal data,” which MODPA defines as information that is linked or can be reasonably linked to an identified or identifiable individual but excludes de-identified data and publicly available information.

    Who Can Enforce?

    Maryland’s attorney general has exclusive enforcement power. With respect to an alleged violation on or before April 1, 2027, the attorney general may issue a notice of violation and a 60-day opportunity to cure it. If the controller or processor fails to remedy the issue within those 60 days, the attorney general can initiate an enforcement action. Penalties can be up to $10,000 per violation, but if the fine is in connection with a repeat violation, it may cost up to $25,000 for each violation.

    Who Is Exempt?

    MODPA includes a short list of entity-level exemptions, including for:

    • Regulatory, administrative, advisory, executive, appointive, legislative, or judicial bodies or instrumentalities of the state of Maryland
    • Nonprofit organizations that process data solely to assist law enforcement in investigating insurance-related criminal or fraudulent acts or first responders to catastrophic events
    • National securities associations under the Securities Exchange Act of 1934 or registered futures associations under the Commodity Exchange Act
    • A financial institution or affiliate subject to the Gramm-Leach-Bliley Act.

    MODPA’s list of data-level exemptions is fairly standard, including data processed in accordance with a variety of federal laws, such as the Health Insurance Portability and Accountability Act (HIPAA), federal research laws and regulations (such as the Common Rule), the Fair Credit Reporting Act, the Drivers Privacy Protection Act, the Family Educational Rights and Privacy Act, the Farm Credit Act of 1971, the Airline Deregulation Act and the Children’s Online Privacy Protection Act, among others.

    What Obligations Are Imposed?

    Controllers under MODPA are subject to several obligations, including requirements to:

    • Limit the collection of personal data to what is reasonably necessary and proportionate to provide or maintain a specific product or service requested by the consumer
    • Avoid processing personal data for secondary reasons (purposes that are neither reasonably necessary nor compatible with the initial disclosed purposes) without the consumer’s prior consent
    • Establish, implement and maintain reasonable administrative, technical and physical data security practices (to protect the confidentiality, integrity and accessibility of personal data appropriate to the volume and nature of the personal data at issue)
    • Not collect, process or share sensitive data except where strictly necessary to provide or maintain a specific consumer-requested product or service
    • Not sell sensitive data
    • Not process personal data in violation of laws that prohibit unlawful discrimination against consumers and refrain from discriminating against consumers who exercise their rights
    • Not process personal data for the purposes of targeted advertising or selling personal data if the controller knew or should have known the personal data related to a consumer under 18 years of age
    • Provide consumers with a reasonably accessible, clear and meaningful privacy notice that includes the disclosures now common under state consumer privacy laws.

    One of the more unique and restrictive aspects of MODPA includes its blanket prohibition on the sale of sensitive data and on any collection, processing or sharing of sensitive data concerning a consumer “except where the collection or processing is strictly necessary to provide or maintain a specific product or service requested by the consumer.”

    To date, no other state privacy law has adopted a prohibition on the sale of sensitive data. Depending on what constitutes a sale, this prohibition could have far-reaching consequences for companies that operate in (e.g., the non-HIPAA-regulated healthcare space) and deploy website tracking technologies.

    What Consumer Rights Are Created By MODPA?

    MODPA provides Maryland consumers with rights that should look familiar by now:

    • The right to confirm whether the controller is processing the consumer’s personal data and to access said data (if being processed)
    • The right to correct personal data, considering the nature of the personal data and the purposes for processing it
    • The right to require the controller to delete personal data provided by or obtained about the consumer, unless required by law to retain
    • The right to data portability when data processing is done through automated means
    • The right to obtain a list of the categories of third parties receiving personal data from the controller
    • Opt-out rights for targeted advertising, the sale of personal data and profiling, where profiling is being used to produce a legal or similarly significant effect
    • The right to appeal rights requests that have not been fulfilled

    Sensitive Data

    MODPA has a list of sensitive data that generally tracks other state consumer privacy laws – but with a twist on consumer health data:

    • Racial or ethnic origin, religious beliefs, consumer health data, sex life, sexual orientation, status as transgender or nonbinary, national origin, or citizenship or immigration status
    • Genetic data or biometric data
    • Personal data collected from a consumer who the controller knows or has reason to know is a child (under 13-year-old)
    • Precise geolocation data (within a 1,750-foot radius).

    Consumer health data under MODPA includes personal data the controller uses to identify a consumer’s physical or mental health status and explicitly includes data related to gender-affirming treatment or reproductive or sexual healthcare. “Physical or mental health status” is not defined. To trigger the defined term, a controller must actually be using data to identify the consumer’s health status.

    Additionally, businesses should note that the law treats any genetic or biometric data as sensitive data, regardless of whether the data is being used to uniquely identify a consumer. This marks another variation from the other states.

    Response to Consumer Requests

    Following the same framework as most states, under MODPA, controllers must respond to a data subject request within 45 days after receipt, with a 45-day extension available as reasonably necessary. If denied, the controller must provide a method to appeal the denial of a request and make the process conspicuously available. A decision on the appeal must be provided within 60 days of receipt of the consumer’s appeal. If an appeal is denied, the decision must include a method for the consumer to submit a complaint with the attorney general.

    Data Protection Assessments

    As expected, MODPA also requires controllers to conduct “data protection assessments” for each processing activity that presents a heightened risk of harm and include an assessment for each algorithm that is used. These types of activities include:

    • Processing personal data for targeted advertising
    • Selling personal data
    • Processing sensitive data
    • Processing personal data for the purposes of profiling, where such profiling presents a reasonably foreseeable risk of unfair, abusive or deceptive treatment of consumers or results in substantial injury to consumers.

    The assessments must identify and compare the processing activity’s benefits that may flow to all parties with potential risks to consumer rights. Like other state privacy laws, MODPA allows impact assessments performed for other state privacy laws to satisfy its assessment requirements. Data protection assessment requirements will apply to processing activities occurring on or after October 1, 2025.

    When Does MODPA Take Effect?

    MODPA goes into effect on October 1, 2025. However, the law will not have any effect on or application to processing activities prior to April 1, 2026.

    ***

    The plethora of unique state privacy laws is becoming more challenging as each new version is introduced. In addition to implementing comprehensive privacy programs, organizations need to ensure they are reviewing applicability and updating internal policies and procedures as needed to maintain compliance.

    If you have questions or need assistance in readiness work for the new state consumer laws, please contact your regular McDermott lawyer or reach out to David Saunders or Allison McSorley Tassel.

    Authors

    David P. Saunders

    Partner

    Chicago

    More insights

  • The PPP Turns Four: Lessons Learned and What Lies Ahead

    The PPP Turns Four: Lessons Learned and What Lies Ahead

    ARTICLE / CLIENT ALERT

    The PPP Turns Four: Lessons Learned and What Lies Ahead

    April 10, 2024

    Read time: 9 min

    Key takeaways
    Overview

    Four years ago this month, lenders began dispersing Paycheck Protection Program (PPP) loans to small businesses in what would become the largest Small Business Administration (SBA) lending program in history. The SBA approved 11,338,996 loans totaling $785,773,859,100. According to the SBA’s most recent report, it has forgiven more than 96% of the total value of all Paycheck Protection Program (PPP) loans.

    However, while most small businesses are relieved to put the pandemic and the PPP in their rearview mirror, many others are still navigating the forgiveness process or may find themselves the subject of a post-forgiveness audit by the SBA – or worse, the target of a civil US Department of Justice (DOJ) False Claims Act investigation.

    In depth

    The SBA’s Audits of Forgiven Loans

    In reaction to Congress and the media raising concerns about fraud within the PPP, the SBA has increasingly turned to post-forgiveness audits to review borrowers’ eligibility for their loans. We have seen an uptick in the number of small businesses that have received a “Notification of Post Payment Paycheck Protection Program Loan Review and Request for Documents” from the SBA. These notifications inform borrowers that even though they have received full loan forgiveness, the SBA has decided to audit their loan and request documents and information to aid the SBA with its review. These notifications often indicate that the SBA is currently recommending a full denial of a previously forgiven loan.

    Borrowers who receive such notifications should be aware that the SBA has the authority to demand repayment of loans even when the borrower has already received forgiveness. Borrowers should take the SBA’s request for documents seriously and compile the requested information where possible. We recommend responding to the SBA with an explanation of why the borrower was eligible for its loan and the forgiveness it received. For example, the SBA is providing borrowers the opportunity to demonstrate eligibility under the alternative size standard, which is a path to eligibility that the SBA failed to clearly communicate to borrowers in the early stages of the PPP rollout, but which borrowers may take advantage of now.

    The False Claims Act and Criminal Enforcement

    Since the outset of the COVID-19 pandemic, the DOJ has devoted extensive resources to criminal and civil enforcement of fraudulent PPP loads. The government created a COVID-19 Fraud Enforcement Task Force along with five COVID-19 Fraud Enforcement Strike Forces with the goal of coordinating national enforcement efforts.

    This week, DOJ’s COVID-19 Fraud Enforcement Task Force released its 2024 report summarizing the government’s enforcement efforts. The report emphasizes that the government has already criminally charged 3,500 defendants in pandemic-fraud-related cases, reached more than 400 civil settlements and recovered more than $1.4 billion in Coronavirus Aid, Relief and Economic Security (CARES) Act funds. These enforcement efforts focused not just on the PPP, but also on recipients of Economic Injury Disaster Loans, unemployment insurance benefits and other CARES Act relief programs. Also this week, in support of these efforts, Senate Democrats (backed by the White House) introduced a $1.3 billion bill to combat pandemic fraud. Among other things, the bill would provide $300 million to triple the COVID-19 Fraud Enforcement Strike Forces, increase the statute of limitations on pandemic fraud to 10 years, increase the cap for administrative recoveries of fraudulent claims, and provide $250 million to the SBA and the US Department of Labor for the express purpose of ensuring they have the resources to investigate pandemic fraud.

    While we expect the government to continue to pursue criminal charges in 2024, we anticipate a particular focus on civil False Claims Act cases. Earlier this year, DOJ announced that False Claims Act settlements and judgments exceeded $2.68 billion in Fiscal Year 2023. This figure resulted from 543 settlements and judgments, the highest number ever in a single year. Of these settlement and judgements, 270 involved PPP loans and the government has recovered more than $48.3 million in improper loans. DOJ’s civil False Claims Act settlements thus far have primarily involved clear matters of ineligibility and DOJ has shown a willingness to invest its resources into investigating small dollar loan recipients.

    In 2024, we expect DOJ to turn its enforcement efforts toward more complex False Claims Act cases involving compliance with the SBA’s numerous PPP regulations. One area we are watching closely is False Claims Act cases that focus on more nuanced legal questions involving issues of affiliation and size eligibility. The COVID-19 Fraud Enforcement Task Force’s 2024 report states that as of this month, DOJ’s Civil Division has opened more than 1,200 civil pandemic fraud matters, including more than 600 qui tam actions filed under the False Claims Act. The report also states that DOJ anticipates “that civil pandemic fraud enforcement will continue to require substantial resources for years to come.”

    As many small businesses probably (painfully) remember, there was much confusion and uncertainty regarding the application of the SBA’s affiliation rules and the size standards applicable to the PPP. The SBA and the US Department of the Treasury released new and sometimes conflicting guidance, rules, and borrower application forms on a near daily basis during an economic and public health crisis that was causing turmoil for small businesses. These small businesses bore the burden of deciphering these constantly evolving rules, as the SBA relieved lenders from the responsibility of verifying instances of eligibility. Hindsight may be 20/20 but in 2020, the SBA gave borrowers no such clarity.

    The SBA’s Efforts to Collect Loans in Default

    In a December 2023 letter to Congress, SBA Administrator Isabella Guzman stressed that the SBA would continue its efforts to collect all unforgiven loans, regardless of amount. Administrator Guzman stated that the SBA will “fully exhaust[] all collection tools at its disposal including direct customer outreach, collateral and personal guarantees, credit reporting, and CAIVRS/Treasury Do Not Pay lists, among others.” She stated that the SBA would extend a grace period for borrowers in default of loans under $100,000 but emphasized that the SBA would seek to collect these loans despite an SBA analysis of the cost benefit of referring loans to the Treasury for collection, which found that it would cost taxpayers more to collect than the anticipated amount recovered.

    We have increasingly seen the SBA and the Treasury levy heavy penalties on borrowers and refer loans to private debt collectors, sometimes without first communicating with borrowers or giving borrowers the chance to craft a repayment plan. These debt collectors are then incentivized to push borrowers for repayment without any concern for the interests of the small businesses. To avoid destroying countless small businesses, the Treasury and the SBA would be wise to allow these loans to be remitted to the SBA to implement a “Workout Plan” that allows the borrower to repay its loan obligation over time.

    The Future of SBA Lending

    Despite recent criticism over the scope of the PPP and the inevitable fraud that comes with any large-scale funding program, many consider the PPP a success. Congress rolled out the PPP mere weeks after states began mandating business closures to fight the spread of COVID-19. Loans began rolling out just days after the program became law.

    In a review of the research conducted on the impact of the PPP, the Bipartisan Policy Center concluded that the balance of research showed that the PPP successfully preserved jobs during the pandemic. One such study conducted by the US Bureau of Labor Statistics showed “an 8% increase in employment, 11.5% increase in wages, and a 5.8% decline in the likelihood of closure within one month of PPP approval.” The Bipartisan Policy Center emphasized that studies showed that the PPP’s impact extended beyond the businesses that received loans and the employees who retained jobs. Small businesses that received loans were able to continue paying rent and purchasing supplies, which had a wider impact on the local economy.

    There are certainly lessons to be learned, however, and studies reveal that the economic boost provided by the PPP was not evenly distributed. While FinTech lenders and community development financial institutions later began processing loans, offering borrowers more lender options, studies have increasingly pointed to FinTech lenders as processing a disproportionate number of fraudulent loans. A staff report from the House Select Subcommittee on the Coronavirus Crisis found that “[d]espite fintechs’ claims that their use of technology and innovation would allow them to better administer the PPP than traditional financial institutions, many of these companies appear to have failed to stop obvious and preventable fraud, leading to the needless loss of taxpayer dollars.”

    Nevertheless, the SBA believes the need to support America’s small businesses outweighs the risk of fraud within relief programs. In testimony before the Senate last month, Administrator Guzman highlighted the importance of America’s 33 million small businesses, which are responsible for nearly two-thirds of net new jobs in this country, employ nearly half of the country’s private sector workforce and produce more than 40% of the country’s economic output. She stated that in 2023 the SBA distributed more than $50 billion to small businesses across its lending, investment and disaster programs. Most recently, the SBA announced that it would extend disaster loans to small businesses impacted by the Baltimore Francis Scott Key Bridge disaster, allowing eligible businesses to apply for long-term loans of up to $2 million at 4% interest.

    Even as SBA audits of PPP loans continue, and even as DOJ increases its civil and criminal PPP enforcement, SBA loans will continue to play an important role in supporting small businesses as they combat an array of economic challenges.

    Authors

    Llewelyn M. Engel

    Partner

    Washington, DC

    Julian L. André

    Partner

    Los Angeles

    More insights

  • FDA Charts Course for Regulating AI Used in Medical Products

    FDA Charts Course for Regulating AI Used in Medical Products

    ARTICLE / CLIENT ALERT

    FDA Charts Course for Regulating AI Used in Medical Products

    April 10, 2024

    Read time: 6 min

    Key takeaways
    Overview

    On March 15, 2024, four of the US Food and Drug Administration’s (FDA) medical products centers released a joint paper, titled “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” outlining how the FDA intends to approach artificial intelligence (AI) use in the medical product life cycle. The paper was issued by the FDA’s Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), Center for Devices and Radiological Health (CDRH) and the Office of Combination Products (OCP) (collectively, the Centers). In it, the Centers discuss plans for forthcoming FDA actions and guidance that the Centers believe balance safeguards for public health and promoting innovation.

    Building on our previous coverage of the FDA’s draft predetermined change control plan for machine-learning (ML)-enabled device software functions and Good Machine Learning Practice Guiding Principles, this On The Subject highlights key FDA actions announced in the joint paper and shares insights on what the joint paper reveals about the Centers’ plans for regulating AI.

    In depth

    In the joint paper, the Centers highlight the need for greater regulatory clarity and collaboration across the sector on standards, best practices and tools for evaluating AI used in medical products. The Centers point out that risk management and monitoring of AI technologies must occur throughout the product life cycle to be effective and acknowledge the importance of risk-based approaches to regulation.

    The Centers hone in on four focus areas for the development and use of AI across the medical product life cycle:

    1. Foster Collaboration To Safeguard Public Health

    The Centers note the need to collaborate and coordinate with stakeholders to develop consistent regulatory approaches and standards for the use of AI in medical products. The Centers promise to work closely with international regulators and a wide range of stakeholders when developing standards for AI evaluation and monitoring. The Centers also seek to promote educational initiatives that support parties across the medical device life cycle who are trying to navigate the responsible use of AI in medical products.

    2. Advance the Development of Regulatory Approaches That Support Innovation

    The Centers promise to monitor trends and identify knowledge gaps with the goal of providing timely, clear guidance on the use of AI in medical products and to support efforts to develop regulatory science methodologies for evaluating AI systems. This includes methods for identifying and mitigating bias and ensuring AI algorithms remain robust in response to changing clinical inputs and conditions. The Centers also intend to issue additional guidance on AI-enabled medical products, including:

    • Final guidance on marketing submission recommendations for predetermined change control plans for AI-enabled device software functions (the draft guidance was issued on April 3, 2023)
    • Draft guidance on life cycle management considerations and premarket submission recommendations for AI-enabled device software functions
    • Draft guidance on considerations for the use of AI to support regulatory decision-making for drugs and biological products.

    3. Promote the Development of Standards, Guidelines, Best Practices and Tools for the Medical Product Life Cycle

    The Centers intend to build off the previously issued Good Machine Learning Practice Guiding Principles to further refine and develop standards, best practices and tools for medical products using AI in their development life cycle. This will include refining metrics for AI transparency, safety and cybersecurity. Developing best practices for ensuring the data used to train AI systems is fit for use (e.g., representative of the target population) is another focus for the Centers. Finally, the Centers intend to identify best practices and develop frameworks for long-term, real-word monitoring and quality assurance of AI-enabled medical products and tools.

    4. Support Research Related to the Evaluation and Monitoring of AI Performance

    Finally, the Centers will support demonstration projects related to AI monitoring and evaluation. The Centers highlighted projects that identify introduction points for bias in the AI life cycle and tools for addressing it, projects targeting sources of health inequity related to AI and the representativeness of data used in AI systems, and projects that develop quality assurance and ongoing monitoring mechanisms for AI tools.

    Key Takeaways

    The joint paper demonstrates that the FDA recognizes the need to provide additional guidance on the use of AI in medical products. The FDA has already released a discussion paper on AI in Drug Manufacturing, the AI/ML SaMD Action Plan and the Predetermined Change Control Plans for Machine Learning-Enabled Medical Devices: Guiding Principles. The joint paper, however, clearly signals more guidance is coming. Notably, the inclusion of the OCP in the paper suggests the FDA is cognizant that effective regulation of AI will require coordinating the jurisdictions of CDER, CBER and CDRH.

    At the same time, the Centers acknowledge that this requires further development of the standards and tools used to evaluate AI systems and measure their performance. The joint paper suggests the FDA will provide the opportunity for stakeholders across the medical product life cycle to participate in shaping best practices and guidelines for monitoring AI-enabled medical products.

    The joint paper is also part of broader federal action related to AI. It comes at a time of increased interest (and scrutiny) from US Congress on how federal agencies will balance AI regulation with continuing to spur innovation. This is acutely felt in the healthcare space. As policymakers continue to understand and grapple with an appropriate amount of regulation and as federal agencies continue to work on implementing the September 30, 2023, executive order on AI, stakeholders should analyze the implications. Specifically for this joint paper, developers, investors and users of AI-enabled medical products should begin considering their approach to AI to best position themselves to participate in shaping the FDA’s ongoing method for regulating AI in medical products and to comply with guidance as it develops.

    For more information on recent FDA guidance on AI in medical products, contact the authors of this article or any other member of McDermott’s Food, Drug & Medical Device Regulatory Group. Additional resources are also available on McDermott’s AI in Healthcare resource center.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Nathan Gray

    Associate

    Washington, DC

    More insights